

1 ***Original research article***

2

3 **Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early after Surgical**

4 **Bioprosthetic Valve Replacement: the ENBALV trial**

5

6 Chisato Izumi, MD, PhD¹, Masashi Amano, MD, PhD¹, Satsuki Fukushima, MD, PhD², Hitoshi Yaku,
7 MD, PhD³, Kiyoyuki Eishi⁴, MD, PhD, Taichi Sakaguchi, MD, PhD⁵, Nobuhisa Ohno, MD, PhD⁶, Arudo
8 Hiraoka, MD, PhD⁷, Kenji Okada, MD, PhD⁸, Yoshikatsu Saiki, MD, PhD⁹, Takashi Miura, MD, PhD¹⁰,
9 Tatsuhiko Komiya, MD, PhD¹¹, Manabu Minami, MD, PhD¹², Haruko Yamamoto, MD, PhD¹², Katsuhiko

10 Omae, PhD¹², for the ENBALV Trial investigators*

11

12 ¹ Department of Heart Failure and Transplant, National Cerebral and Cardiovascular Center, Suita, Japan

13 ² Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan

14 ³ Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan

15 ⁴ Department of Cardiovascular Surgery, Hakujuji Hospital, Fukuoka, Japan

16 ⁵ Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya, Japan

17 ⁶ Department of Cardiovascular Surgery, Kokura Memorial Hospital

18 ⁷ Department of Cardiovascular Surgery, Sakakibara Heart Institute of Okayama

19 ⁸ Department of Cardiovascular Surgery, Kobe University Graduate School of Medicine

20 ⁹ Department of Cardiovascular Surgery, Tohoku University Graduate School of Medicine

21 ¹⁰ Department of Cardiovascular Surgery, Nagasaki University Graduate School of Biomedical Sciences

22 ¹¹ Department of Cardiac Surgery, Kurashiki Central Hospital

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 ¹² Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan

24

25

26 * A full list of the investigators in the ENBALV trial is provided in the Supplemental
27 material.

28

29 Running title; edoxaban early after bioprosthetic valve surgery

30

31 Address for correspondence: Chisato Izumi, MD, PhD

32 ORCHiD: <https://orcid.org/0000-0002-3282-1327>

33 Director, Department of Heart Failure and Transplantation, National Cerebral and
34 Cardiovascular Center, 6-1 Kishibe Shimmachi, Suita, Osaka 564-8565 Japan.

35 Tel: +81-661701070

36 Fax: +81-661701069

37 E-mail: izumi-ch@nccvc.go.jp

38

39 Total word count: 3104 (5651 including title page, abstract, text, references, tables, and figure
40 legends)

41

42

43 **Abstract**

44

45 **Background**

46 Anticoagulant therapy with vitamin K antagonists is recommended in the current guidelines
47 for 3 to 6 months following bioprosthetic valve replacement to prevent thromboembolic
48 events, including in patients with sinus rhythm. However, in the era of direct oral
49 anticoagulants (DOACs), there is a paucity of evidence regarding the efficacy and safety of
50 DOACs in this patient group.

51 **Methods**

52 The ENBALV trial was an investigator-initiated, phase 3, randomized, open-label,
53 multicenter study that aimed to evaluate the efficacy and safety of edoxaban compared to
54 warfarin within 3 months following bioprosthetic valve replacement at the aortic and/or
55 mitral position. The primary outcome was stroke or systemic embolism. The secondary
56 outcomes included major bleeding, intracardiac thrombus, and a composite of stroke,
57 systemic embolism, or major bleeding.

58 **Results**

59 Of 410 enrolled patients, 389 were included in the final analysis (73±6 years, 56.8% male,
60 79.4% sinus rhythm, edoxaban group: n=195, warfarin group: n=194). The primary outcome
61 occurred in 0.5% (n=1) in the edoxaban group, whereas in 1.5% (n=3) in the warfarin group

62 (risk difference, -1.03, 95% confidence interval [CI], -4.34 to 1.95). Major bleeding
63 occurred in 4.1% (n=8) in the edoxaban group and in 1.0% (n=2) in the warfarin (risk
64 difference, 3.07; 95% CI, -0.67 to 7.27). The incidence of major bleeding was numerically
65 higher in the edoxaban group, but no fatal bleeding or intracranial hemorrhage was observed
66 in patients treated with edoxaban, whereas one fatal intracranial hemorrhage occurred in the
67 warfarin group. Intracardiac thrombus did not occur in any of the patients in the edoxaban
68 group, but did occur in 1.0% (n=2) in the warfarin group.

69 **Conclusions**

70 Edoxaban had comparable efficacy to warfarin for the prevention of thromboembolic events
71 in patients early after bioprosthetic valve replacement, suggesting that it is a potential
72 alternative anticoagulant therapy.

73

74 **Trial registration**

75 The study was registered with the Japan Registry of Clinical Trials (JRCT), with reference
76 number 2051210209 (30 March 2022; <https://jrct.niph.go.jp/latest-detail/jRCT2051210209>).

77

78 **Key words**

79 Anticoagulant, Bioprosthetic valve, Cardiac surgery, Embolism, Hemorrhage

80

81 **Clinical perspective**

82

83 **What is new?**

84 ● Current guidelines recommend the administration of warfarin for patients early after
85 bioprosthetic valve replacement, including those with sinus rhythm, but there is a paucity
86 of evidence regarding the efficacy and safety of direct oral anticoagulants (DOACs) in
87 this patient group.

88 ● ENBALV trial provides the first large-scale evidence on the use of DOAC in patients
89 early after bioprosthetic valve surgery.

90 ● ENBALV trial demonstrated that edoxaban had comparable efficacy to warfarin for
91 preventing thromboembolism. No fatal or intracranial hemorrhage was observed with
92 edoxaban. Our results suggest that edoxaban could be an alternative to warfarin in this
93 patient group.

94

95 **What are the clinical implications?**

96 ● The availability of edoxaban could offer more flexibility in anticoagulant treatment
97 options after bioprosthetic valve surgery. Since edoxaban does not require regular and
98 frequent blood testing, it could simplify the care process, reduce the burden on patients,
99 and improve their quality of life, especially in the crucial early period after surgery.

- 100 ● The availability of edoxaban also give benefits for medical stuffs as well as patients,
101 because edoxaban can be used with constant dose, no need of routine monitoring of
102 anticoagulation activity, and a low risk of interaction with other drugs and food.
103

104 **Introduction**

105

106 The number of patients with valvular heart disease has been increasing and this trend has
107 been paralleled by an increase in the prevalence of bioprosthetic valve replacement with
108 aging society.¹ The incidence of embolic events has been reported to be high early after
109 bioprosthetic valve replacement;²⁻⁶ therefore, anticoagulant therapy with vitamin K
110 antagonists is recommended in the current guidelines for 3 to 6 months following
111 bioprosthetic valve replacement to prevent thromboembolic events, including in patients with
112 sinus rhythm.⁷⁻⁹

113 Randomized clinical trials have demonstrated the efficacy and safety of direct oral
114 anticoagulants (DOACs) versus warfarin for the treatment of patients with nonvalvular atrial
115 fibrillation (AF),¹⁰⁻¹² and DOACs have become widely used, because the routine monitoring
116 of anticoagulation activity is not required and there is a low risk of interaction with other
117 drugs and food.

118 Evidence supporting the use of DOACs in patients with AF who have undergone
119 bioprosthetic valve replacement has been provided by several subgroup analyses of
120 randomized clinical trials¹³⁻¹⁵ and observational studies¹⁶⁻¹⁸. In addition, a randomized
121 clinical trial that compared the use of rivaroxaban and warfarin in patients with AF and a
122 bioprosthetic mitral valve¹⁹ revealed the non-inferiority of rivaroxaban to warfarin with

123 respect to a composite outcome of death, major cardiovascular events, or major bleeding.
124 However, fewer than 20% (n=189) of the participants had undergone bioprosthetic valve
125 replacement within the preceding 3 months, and there were no participants with sinus rhythm.
126 In addition, another study demonstrated the efficacy and safety of edoxaban versus warfarin
127 in patients who underwent mitral valve repair or bioprosthetic valve replacement, but the
128 bioprosthetic valve replacement group was small (n=152).²⁰

129 The efficacy and safety of EdoxabaN in anticoagulant therapy after surgical
130 Bioprosthetic vALVe replacement (ENBALV) trial was a randomized clinical trial that aimed
131 to evaluate the efficacy and safety of edoxaban compared to warfarin early after bioprosthetic
132 valve replacement.

133

134 **Methods**

135

136 ***Trial design and oversight***

137 The trial design has been described previously.²¹ Briefly, the ENBALV trial was an
138 investigator-initiated, phase 3, randomized, open-label, multicenter study. We evaluated the
139 efficacy and safety of the use of edoxaban compared to warfarin within 3 months following
140 bioprosthetic valve replacement. Details of the participating investigators and trial
141 organization are provided in the Supplementary material.

142 All the procedures involving human participants were performed in accordance with the
143 1964 Declaration of Helsinki and its later amendments or comparable ethical standards, and
144 with the Japanese Pharmaceutical Affairs Act and related laws and regulations. The study
145 protocol was approved by the National Cerebral and Cardiovascular Center Review Board in
146 addition to the Institutional Review Board of each participating institution and it was
147 registered with the Japan Registry of Clinical Trials (jRCT 2051210209). Written informed
148 consent was obtained from all the patients before they were recruited.

149 An independent safety monitoring committee monitored all the safety data and was
150 involved in decisions regarding trial continuation or protocol changes. All suspected
151 outcomes and the results of imaging evaluations were adjudicated by an independent event
152 committee, the members of which were unaware of the trial group assignments.

153

154 ***Trial population***

155 We studied patients aged 18 to 85 years who underwent bioprosthetic valve replacement at
156 the aortic and/or mitral position. Patients with both sinus rhythm and AF were included. The
157 main exclusion criteria were a contraindication to the use of either warfarin or edoxaban, an
158 extremely high risk of hemorrhage, and the presence of a mechanical valve or greater than
159 moderate mitral stenosis, except if replacement of the mechanical valve or stenotic mitral
160 valve by a bioprosthetic valve was performed at this operation. Further details regarding the

161 inclusion and exclusion criteria of the ENBALV trial are shown in Table S1. To minimize the
162 risk of withdrawal because of worsening renal function after surgery, the patient selection
163 criterion for renal function was set as a creatinine clearance of ≥ 30 mL/min, not ≥ 15 mL/min.

164

165 *Trial procedures*

166 Eligible patients were randomly allocated to either the edoxaban or warfarin group at a 1:1
167 ratio using a web-based randomization system and the minimization method. The adjustment
168 factors were 1) the valve position (aortic valve alone, mitral valve alone, or both valves), 2)
169 the presence of AF, and 3) the administration of antiplatelet drugs.

170 Bioprosthetic valve replacement was performed within 8 weeks of randomization.
171 Edoxaban or warfarin administration was started following bioprosthetic valve replacement,
172 as soon as the surgeons had determined that it was appropriate for anticoagulant therapy to
173 commence. Anticoagulant therapy initiation could be delayed according to patients' condition
174 such as postoperative wound bleeding. The present study was performed during the unstable
175 period immediately following open heart surgery; therefore, the surgeons could use their
176 discretion to determine when anticoagulant therapy should be initiated, to prioritize patient
177 safety.

178 Edoxaban was orally administered at the dose of 60 mg once daily, or 30 mg once daily
179 when the patient's creatinine clearance was 30 to 50 mL/min (calculated using the

180 Cockcroft–Gault equation), their body weight was ≤ 60 kg, or they were being concomitantly
181 treated with a P-glycoprotein inhibitor. The dose of warfarin was adjusted under monitoring
182 the prothrombin time-international normalized ratio (PT-INR). Administration of edoxaban
183 or warfarin was continued for 12 weeks after surgery if the patient did not meet any of the
184 criteria for its discontinuation, and their administration could be continued until 24 weeks at
185 the surgeons' discretion. Clinical evaluations were conducted from the initiation of study
186 drug administration to the end of study treatment.

187 The patients underwent clinical assessment and laboratory testing 1 and 7 days after the
188 administration of edoxaban or warfarin commenced and at discharge. After discharge, they
189 were scheduled to visit an outpatient clinic 4, 8, and 12 weeks after initiation of anticoagulant
190 therapy. Clinical assessments, including the evaluation of symptoms suggestive of clinical
191 thromboembolic or hemorrhagic events and laboratory testing, were performed at the
192 outpatient visits.

193 The patients underwent a 12-lead electrocardiography and transthoracic
194 echocardiography as part of eligibility assessment prior to randomization, at discharge, and
195 12 weeks after initiation of anticoagulant therapy. Brain magnetic resonance imaging (MRI)
196 or computed tomography (CT) was also performed during the eligibility assessment process
197 prior to randomization and 12 weeks after initiation of anticoagulant therapy.

198

199 ***Primary and secondary outcomes***

200 The primary outcome was a composite of stroke or systemic embolism. The key
201 secondary outcomes were major bleeding, intracardiac thrombus, and a composite of stroke,
202 systemic embolism, or major bleeding, according to the definition of the International Society
203 on Thrombosis and Haemostasis. The secondary outcomes also included the individual
204 components of the composite outcome and other clinical events. A complete list of trial
205 endpoints is provided in Table S2.

206

207 ***Statistical analysis***

208 The event rates for the primary endpoints in the study and control treatment groups were
209 estimated to be 1% to 3%, based on historical reports.²⁻⁵ Thus, the difference in the event rate
210 between the control and study treatment groups was not expected to be very large.
211 Furthermore, the number of patients that could be included within a reasonable study period
212 was estimated to be approximately 450, and it was judged not to be reasonable to conduct a
213 non-inferiority trial on this scale to test the hypothesis. Therefore, to determine whether the
214 study drug was not significantly inferior to the control drug, we decided to evaluate whether
215 the difference in the point estimates of the event rate for the primary endpoint was below a
216 certain threshold. A previous study² that included data from a no-treatment group estimated
217 that the event rate within 3 months after surgery in the absence of treatment was >7%. On

218 this basis, the experts in our study group determined that 2% is a clinically acceptable and
219 reasonable threshold for the difference in event rate between the treatment and control groups.
220 Given the 450 enrolled patients, 1:1 allocation, and a dropout rate of approximately 10%, the
221 primary endpoint was expected to be assessed in 202 patients in each group. The event rates p
222 and q for the treatment and control groups were assumed to follow a uniform distribution
223 within the interval [0.01, 0.03], and the occurrence of events in the treatment and control
224 groups were assumed to follow a Bernoulli distribution with occurrence probabilities p and q ,
225 respectively. Under these conditions, the probability that the point estimate of $p-q$ is $<2\%$
226 was evaluated by a simulation study and estimated to be approximately 90%. On the basis of
227 the above considerations, the target number of patients to be enrolled in the trial was set as
228 450.

229 The primary analysis of the trial data was performed in a full analysis set (FAS) based
230 on intention-to-treat principles. The FAS consisted of all the assigned study participants,
231 excluding those who did not meet the primary enrollment criteria, those who never received
232 any study treatments, those for whom post-assignment data were not available, and those who
233 withdrew consent for the use of their data. The point estimate of the event rate for the primary
234 endpoint was calculated for each of the study and control treatment groups to determine
235 whether the difference in event rates was $\leq 2\%$. As an additional analysis, a similar evaluation
236 was conducted on the per-protocol set, a population of the FAS that excludes subjects who

237 were found to have violations or deviations from the study protocol that would affect the
238 evaluation of the primary endpoint. Other endpoints were summarized and compared by
239 groups, with subpopulation analyses conducted as necessary. All analyses were performed
240 using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).

241

242 **Results**

243

244 *Patient backgrounds and follow-up*

245 Between May 6, 2022, and January 25, 2024, a total of 430 patients gave their consent to
246 participate and were assessed for eligibility at 24 institutions. Of these, 410 patients
247 underwent randomization (205 were assigned to receive edoxaban and 205 were assigned to
248 receive warfarin). Of these 410 patients, 21 did not receive edoxaban or warfarin; therefore,
249 389 patients were included in the final analysis (edoxaban group, n=195; warfarin group,
250 n=194) (Figure 1).

251 The clinical characteristics of the patients are shown in Table 1. The two groups were
252 well balanced with respect to their baseline characteristics. The mean age was 73 years,
253 including 42 (10.8%) patients of ≥ 80 years of age, and 56.8% were male. The CHADS₂ score,
254 CHA₂DS₂-VASc score, and HAS-BLED score were 2.0 ± 1.2 , 3.4 ± 1.4 , and 1.1 ± 0.6 ,
255 respectively. Positions of bioprosthetic valve were aortic valve only in 339 (87.1%) patients,

256 mitral valve only in 37 (9.5%) patients, and both in 13 (3.3%) patients. Of the 389 patients,
257 67 (17.2%) were taking antiplatelet drugs and 80 (20.6%) had atrial fibrillation, namely, the
258 majority of patients had sinus rhythm.

259 The date of the last patient follow-up was April 25, 2024. The median duration of
260 participation in the trial was 98 days (interquartile range, 92 to 106 days). Of the 389 patients,
261 20 in the edoxaban group (11 discontinued edoxaban because of adverse events, and nine
262 were judged as lack of capability to continue participation in the trial) and 17 in the warfarin
263 group (six discontinued warfarin because of adverse events, two withdrew their consent, eight
264 were judged as lack of capability to continue participation in the trial, and one died) did not
265 complete the trial.

266 The patients in the warfarin group had PT-INR values within the therapeutic range
267 (2.0–3.0 seconds) for a median of 19.0% (interquartile range, 7.0%–31.4%) of the study
268 period.

269

270 ***Primary and secondary outcomes***

271 The primary outcome occurred in one patient (0.5%) in the edoxaban group, whereas in
272 three patients (1.5%) in the warfarin group (risk difference, -1.03 ; 95% confidence interval
273 [CI], -4.34 to 1.95) (Figures 2 and 3A). Systemic embolism did not occur in any of the study
274 patients; thus all of the events of primary outcome were stroke. Intracardiac thrombus did not

275 occur in any of the patients in the edoxaban group, but did occur in two patients (1.0%) in the
276 warfarin group (risk difference, -1.03 ; 95% CI, -4.07 to 1.52) (Figures 2 and 3B).

277 Major bleeding occurred in eight patients (4.1%) in the edoxaban group and in two
278 patients (1.0%) in the warfarin group (risk difference, 3.07 ; 95% CI, -0.67 to 7.27) (Figures 2
279 and 3C). The sites of the major bleeding in each group are shown in Table S3. No fatal
280 bleeding or intracranial hemorrhage was observed in patients treated with edoxaban despite
281 high incidence of gastrointestinal bleeding. In the warfarin group, one patient died of cerebral
282 hemorrhage. Clinically relevant hemorrhage occurred in 11 patients (5.6%) taking edoxaban
283 and five (2.6%) taking warfarin (risk difference, 3.06 ; 95% CI, -1.46 to 7.84).

284 The net outcome (the composite of stroke, systemic embolism, or major bleeding)
285 occurred in nine patients (4.6%) in the edoxaban group and in four patients (2.1%) in the
286 warfarin group (risk difference, 2.55 ; 95% CI, -1.64 to 7.02) (Figures 2 and 3D).

287 The incidences of the other secondary outcomes were also similar for the two groups
288 (Figure 2).

289

290 ***Results of the subgroup analysis***

291 The incidences of the primary endpoint in the two groups were generally consistent across all
292 the prespecified subgroups (Figure 4). With respect to major bleeding and the net outcome,
293 the results were also generally consistent across all the prespecified subgroups (Figures S1

294 and S2).

295

296 **Discussion**

297

298 The present study provides the first large-scale evidence on the use of DOAC in patients
299 early after bioprosthetic valve surgery. Notably, approximately 80% of the study patients had
300 sinus rhythm.

301 The incidence of embolic events has been reported to be high early after bioprosthetic
302 valve replacement.^{2-6, 22} This high incidence of thromboembolic events may be caused by
303 thrombus formation associated with the lack of endothelialization of prosthetic valves,²³ the
304 high prevalence of perioperative AF, and cardiac dysfunction early after bioprosthetic valve
305 surgery. Therefore, current guidelines⁷⁻⁹ recommend anticoagulant therapy with vitamin K
306 antagonists for 3 to 6 months following bioprosthetic valve replacement.

307 Warfarin has a narrow therapeutic range. Therefore, we need to adjust the dose of
308 warfarin by blood monitoring of anticoagulation activity, and it takes a few days to enter the
309 therapeutic range. In contrast, we can use constant dose of edoxaban determined by body
310 weight, renal function and concurrent drugs, with no need of routine monitoring of
311 anticoagulation activity. The effects of edoxaban emerge within 3 hours after administration,
312 and edoxaban as well as other DOACs have a low risk of interaction with other drugs and

313 food. The prevalence of DOAC administration has been increasing, and DOACs are
314 prescribed in approximately 70% of patients with newly diagnosed AF, because of the
315 aforementioned properties of DOAC.²⁴⁻²⁶ These properties are beneficial for patients early
316 after cardiac surgery, when their condition is unstable. According to the results of a database
317 analysis performed in the United States in 2020, the administration of DOACs at the time of
318 discharge following bioprosthetic valve replacement had been increasing since 2011 in
319 real-world clinical practice, despite this being off-label use in patients with sinus rhythm.²⁷

320 Several studies have shown the efficacy and safety of DOACs in patients with a history
321 of bioprosthetic valve replacement and AF.¹³⁻¹⁹ However, in the era of DOACs, there is a
322 paucity of evidence regarding the efficacy and safety of DOACs in patients early after
323 bioprosthetic valve replacement including patients with sinus rhythm.²⁰

324 The results of the ENBALV trial demonstrate that edoxaban is comparable to warfarin
325 with respect to the primary endpoint of stroke or systemic embolism in patients early after
326 bioprosthetic valve replacement. The results of this clinical study met the primary endpoint,
327 which was agreed by the Japanese Regulatory Pharmaceuticals and Medica Devices Agency.
328 In addition, intracardiac thrombus did not occur in any of the patients taking edoxaban, but
329 did occur in two patients taking warfarin. Thus, in patients early after bioprosthetic valve
330 replacement, who are at a high risk of thromboembolic events, edoxaban showed efficacy
331 compared to warfarin for the prevention of thromboembolic event and intracardiac thrombus

332 formation.

333 The incidence of major bleeding events was numerically higher in the edoxaban group
334 (4.1% vs 1.0%; risk difference, 3.07; 95% CI, -0.67 to 7.27). However, fatal bleeding or
335 intracranial hemorrhage did not occur despite high incidence of gastrointestinal bleeding. On
336 the other hand, one patient died of cerebral hemorrhage in the warfarin group. In addition, the
337 incidence of major bleeding in the edoxaban group in the present study was similar to that
338 identified in previous studies^{2, 3, 5, 20, 28, 29} evaluating clinical events early after bioprosthetic
339 valve replacement.

340 The time in therapeutic range in the warfarin group was very short (19.0%) in the
341 present study. During the unstable period immediately following open heart surgery, there is
342 a significant risk of hemorrhage; therefore, surgeons tend to underdose patients, such that
343 their PT-INRs are shorter than would be ideal. In addition, it is difficult to achieve
344 appropriate therapeutic range of warfarin during the relatively short period of hospitalization.
345 The short time in therapeutic range may influence on the occurrence rate of embolic events
346 and bleeding. However, this undertreatment with warfarin reflects the current clinical
347 situation and is precisely the problem associated with warfarin administration. Increase in
348 treatment option of anticoagulant therapy early after cardiac surgery may have clinical
349 advantages, because the conditions of the patients are highly variable during this period. It
350 may give benefits for medical stuffs as well as patients, because edoxaban can be used with

351 constant dose, no need of routine monitoring of anticoagulation activity, and a low risk of
352 interaction with other drugs and food.

353 The present study had several limitations. First, the open-label protocol could have
354 introduced bias. Warfarin should be administered with monitoring of dose adjustments using
355 the PT-INR, whereas the dose of edoxaban is constant, determined by renal function and
356 body weight, not the PT-INR. Therefore, we were unable to blind the participants or their
357 physicians with regard to the treatment group. However, outcome assessments were
358 conducted by assessors who were blinded to the treatment allocation. In addition, data
359 management and monitoring were performed by independent clinical research entities to
360 minimize the risk of bias. Second, the timing of the initiation of anticoagulant therapy was
361 determined by the surgeons, which may have influenced the incidences of the clinical events.
362 However, the present study was of patients in an unstable condition immediately after
363 open-heart surgery, and therefore the study protocol was designed to prioritize patient safety.
364 Third, we did not include patients undergoing transcatheter aortic valve replacement.
365 However, the strategy of antithrombotic therapy after bioprosthetic valve replacement differs
366 for patients who undergo surgical or transcatheter aortic valve replacement, according to the
367 current guidelines.⁷⁻⁹ Therefore, the study population was limited to patients undergoing
368 surgical bioprosthetic valve replacement.

369 In conclusion, edoxaban demonstrated comparable efficacy to warfarin for the

370 prevention of thromboembolic events in patients early after undergoing bioprosthetic valve

371 replacement, suggesting that it is a potential alternative anticoagulant therapy.

372

373

374 **Acknowledgments**

375 We thank all the investigators (listed in the Supplemental Materials) and the study nurses
376 /study coordinators involved in the ENBALV trial, and the staff members of DOT WORLD
377 Co., Ltd for their assistance in the management of data collection, storage, and analysis.

378 We also thank Mark Cleasby, PhD from Edanz (<https://jp.edanz.com/ac>) for editing a draft of
379 this manuscript.

380

381 **Sources of funding**

382 This investigator-initiated trial was funded by Daiichi Sankyo Co., Ltd.

383

384 **Disclosures**

385 Dr Izumi has received speaker honoraria from Daiichi Sankyo Co., Ltd., Nippon Boehringer
386 Ingelheim, and Novartis and research funding from Pfizer, LSI Medience Co., PPD-SNBL
387 K.K., Abbott Medical Japan, Bristol-Myers Squibb, and Eli Lilly and Company.

388 Dr. Sakaguchi has received speaker honoraria from Abbott Medical Japan and Medtronic
389 Japan.

390 The other authors have no relevant financial or non-financial interests to disclose.

391

392

393

394 **Supplemental material**

395 List of investigators

396 Trial committee members

397 Tables S1–S3

398 Figures S1–S2

399

400

401 **References**

402

403 1. Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve
404 replacement. *Eur Heart J*. 2017;38:2183–2191. doi: 10.1093/eurheartj/ehx141

405 2. Mérie C, Køber L, Olsen PS, Andersson C, Gislason G, Jensen JS, Torp-Pedersen C.
406 Association of warfarin therapy duration after bioprosthetic aortic valve replacement
407 with risk of mortality, thromboembolic complications, and bleeding. *JAMA*.
408 2012;308:2118–2125. doi: 10.1001/jama.2012.54506

409 3. Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas
410 PS, Peterson ED; DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic
411 aortic valves in older patients: results from the Society of Thoracic Surgeons Adult
412 Cardiac Surgery National Database. *J Am Coll Cardiol*. 2012;60:971–977. doi:
413 10.1016/j.jacc.2012.05.029

414 4. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK,
415 Orszulak TA, Pluth JR, Puga FJ, et al. High risk of thromboemboli early after
416 bioprosthetic cardiac valve replacement. *J Am Coll Cardiol*. 1995;25:1111–1119. doi:
417 10.1016/0735-1097(94)00563-6

418 5. Zhang H, Dong Y, Ao X, Fu B, Dong L; CLIATHVR (Chinese Low Intensity
419 Anticoagulant Therapy After Heart Valve Replacement) multicenter clinical study team.

- 420 Comparison of antithrombotic strategies in Chinese patients in sinus rhythm after
421 bioprosthetic mitral valve replacement: early outcomes from a multicenter registry in
422 China. *Cardiovasc Drugs Ther.* 2021;35:1–10. doi: 10.1007/s10557-020-07069-8
- 423 6. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, Brown R,
424 Sundt T, Enriquez-Sarano M. Thromboembolic complications after surgical correction of
425 mitral regurgitation incidence, predictors, and clinical implications. *J Am Coll Cardiol.*
426 2008;51:1203–1211. doi: 10.1016/j.jacc.2007.10.058
- 427 7. Izumi C, Eishi K, Ashihara K, Arita T, Otsuji Y, Kunihara T, Komiya T, Shibata T,
428 Seo Y, Daimon M, et al. JCS/JSCS/JATS/JSVS 2020 Guidelines on the management of
429 valvular heart disease. *Circ J.* 2020;84:2037–2119. doi: 10.1253/circj.CJ-20-0135
- 430 8. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin 3rd JP, Gentile F, Jneid
431 H, Krieger EV, Mack M, McLeod C, et al. 2020 ACC/AHA Guideline for the
432 management of patients with valvular heart disease: executive summary: a report of the
433 American College of Cardiology/American Heart Association Joint Committee on
434 Clinical Practice Guidelines. *Circulation.* 2021;143:e35–e71. doi:
435 10.1161/CIR.0000000000000932
- 436 9. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno
437 D, Conradi L, De Bonis M, De Paulis R, et al. 2021 ESC/EACTS Guidelines for the
438 management of valvular heart disease. *Eur Heart J.* 2022;43:561–632. doi:

439 10.1093/eurheartj/ehab395

440 10. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo
441 AL, Ezekowitz MD, Weitz JI, Špinar J, et al. Edoxaban versus warfarin in patients with
442 atrial fibrillation. *N Engl J Med*. 2013;369:2093–2104. doi: 10.1056/NEJMoa1310907

443 11. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M,
444 Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients
445 with atrial fibrillation. *N Engl J Med*. 2011;365:981–992. doi: 10.1056/NEJMoa1107039

446 12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
447 Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular
448 atrial fibrillation. *N Engl J Med*. 2011;365:883–891. doi: 10.1056/NEJMoa1009638

449 13. Avezum A, Lopes RD, Schulte PJ, Lanus F, Gersh BJ, Hanna M, Pais P, Erol C,
450 Diaz R, Bahit MC, et al. Apixaban in comparison with warfarin in patients with atrial
451 fibrillation and valvular heart disease: findings from the Apixaban for Reduction in
452 Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
453 *Circulation*. 2015;132:624–632. doi: 10.1161/CIRCULATIONAHA.114.014807

454 14. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F,
455 Mercuri MF, Antman E, Giugliano RP, et al. Edoxaban for the prevention of
456 thromboembolism in patients with atrial fibrillation and bioprosthetic valves. *Circulation*.
457 2017;135:1273–1275. doi: 10.1161/CIRCULATIONAHA.116.026714

- 458 15. Guimarães PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A,
459 Carnicelli A, Lewis BS, Hanna M, Wallentin L, et al. Efficacy and safety of apixaban vs
460 warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or
461 valve repair: insights from the ARISTOTLE trial. *Clin Cardiol.* 2019;42:568–571. doi:
462 10.1002/clc.23178
- 463 16. Guimaraes HP, Lopes RD, de Barros e Silva PGM, Liporace IL, Sampaio RO,
464 Tarasoutchi F, Hoffmann-Filho CR, Patriota RdeLS, Leiria TLL, Lamprea D, et al.
465 Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. *N Engl J*
466 *Med.* 2020;383:2117–2126. doi: 10.1056/NEJMoa2029603
- 467 17. Izumi C, Miyake M, Fujita T, Koyama T, Tanaka H, Ando K, Komiya T, Izumo M,
468 Kawai H, Eishi K, et al. Antithrombotic therapy for patients with atrial fibrillation and
469 bioprosthetic valves – real-world data from the multicenter, prospective, observational
470 BPV-AF Registry. *Circ J.* 2022;86:440–448. doi: 10.1253/circj.CJ-21-0564
- 471 18. Suppah M, Kamal A, Saadoun R, Baradeiya AMA, Abraham B, Alsidawi S, Sorajja
472 D, Fortuin FD, Arsanjani R. An evidence-based approach to anticoagulation therapy
473 comparing direct oral anticoagulants and vitamin K antagonists in patients with atrial
474 fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network
475 meta-analysis. *Am J Cardiol.* 2023;206:132–150. doi: 10.1016/j.amjcard.2023.07.141
- 476 19. Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of

- 477 direct oral anticoagulants and warfarin after bioprosthetic valve replacements. *Clin Drug*
478 *Investig.* 2020;40:839–845. doi: 10.1007/s40261-020-00939-x
- 479 20. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, Hong G-R. Efficacy and
480 safety of edoxaban in patients early after surgical bioprosthetic valve implantation or
481 valve repair: a randomized clinical trial. *J Thorac Cardiovasc Surg.* 2023;165:58–67.
482 doi: 10.1016/j.jtcvs.2021.01.127
- 483 21. Izumi C, Amano M, Fukushima S, Yaku H, Eishi K, Sakaguchi T, Minami M,
484 Yamamoto H, Onda K, Omae K. Efficacy and safety of edoxaban in anticoagulant
485 therapy early after surgical bioprosthetic valve replacement: rationale and design of the
486 ENBALV trial. *Cardiovasc Drugs Ther.* 2024 Jun 24. doi:
487 10.1007/s10557-024-07585-x. Online ahead of print.
- 488 22. Chang WT, Ho CH, Chang CL, Cheng BC, Wu NC, Chen ZC. Influence of warfarin
489 on cardiac and cerebrovascular events following bioprosthetic aortic valve replacement:
490 a nationwide cohort study. *J Thorac Cardiovasc Surg.* 2020;159:1730–1739. doi:
491 10.1016/j.jtcvs.2019.04.096
- 492 23. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch
493 FM, Ruiz CE, Olsen NT, Trento A, et al. Possible subclinical leaflet thrombosis in
494 bioprosthetic aortic valves. *N Engl J Med.* 2015;373:2015–2024. doi:
495 10.1056/NEJMoa1509233

- 496 24. Gadsbøll K, Staerk L, Fosbøl EL, Sindet-Pedersen C, Gundlund A, Lip GYH,
497 Gislason GH, Olesen JB. Increased use of oral anticoagulants in patients with atrial
498 fibrillation: temporal trends from 2005 to 2015 in Denmark. *Eur Heart J.* 2017;38:899–
499 906. doi: 10.1093/eurheartj/ehw658
- 500 25. Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral
501 anticoagulation therapy use in patients with atrial fibrillation after the introduction of
502 non-vitamin K antagonist oral anticoagulants: findings from the French healthcare
503 databases, 2011–2016. *BMJ Open.* 2019;9:e026645. doi:10.1136/bmjopen-2018-026645
- 504 26. Koretsune Y, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Shimizu W,
505 Tsutsui H, Toyoda K, Hirayama A, et al. Baseline demographics and clinical
506 characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. *Circ J*
507 2019;83:1538–1545. doi: 10.1253/circj.CJ-19-0094
- 508 27. Beller JP, Krebs ED, Hawkins RB, Mehaffey JH, Quader MA, Speir AM, Kiser AC,
509 Joseph M, Yarboro LT, Teman NR, et al. Non-vitamin K oral anticoagulant use after
510 cardiac surgery is rapidly increasing. *J Thorac Cardiovasc Surg.* 2020;160:1222–1231.
511 doi: 10.1016/j.jtcvs.2019.09.064
- 512 28. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early
513 antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal
514 sinus rhythm? *J Thorac Cardiovasc Surg.* 2010;139:1137–1145. doi:

515 10.1016/j.jtcvs.2009.10.064

516 29. Bravata DM, Coffing JM, Kansagara D, Myers J, Murphy L, Homoya BJ, Perkins

517 AJ, Snow K, Quin JA, Zhang Y, et al. Association between antithrombotic medication

518 use after bioprosthetic aortic valve replacement and outcomes in the Veterans Health

519 Administration System. *JAMA Surg.* 2019;145:e184679. doi:

520 10.1001/jamasurg.2018.4679

521

522 **Figure legends**

523

524 **Figure 1.** Enrollment, randomization, and follow-up of the patients

525 **Figure 2.** Primary and secondary endpoints

526 **Figure 3.** Kaplan–Meier analysis of the primary and key secondary endpoints

527 A: Primary endpoint. B: Intracardiac thrombus. C: Major bleeding. D: Net outcome
528 (composite of stroke, systemic embolism, or major bleeding).

529 **Figure 4.** Results of the subgroup analysis of the primary endpoint

530 Ccr, creatinine clearance.

531

Table 1: Demographic and Clinical Characteristics of the Patients

Characteristic	All Patients (N=389)	Edoxaban (N=195)	Warfarin (N=194)
Age,			
Mean± SD, yr	72.7 ± 6.1	72.9 ± 6.3	72.5 ± 5.8
Distribution			
<65yr	33 (8.5)	16 (8.2)	17 (8.8)
≥65 yr and <75 yr	204 (52.4)	93 (47.7)	111 (57.2)
≥75 yr and <80 yr	90 (28.3)	69 (35.4)	41 (21.1)
≥80 yr	42 (10.8)	17 (8.7)	25 (12.9)
Male sex-no. (%)	221 (56.8)	100 (51.3)	121 (62.4)
Weight			
Mean± SD, kg	60.6 ± 11.4	59.0 ± 10.6	62.3 ± 12.0
Distribution			
≤60kg	194 (49.9)	110 (56.4)	84 (43.3)
>60Kg	195 (50.1)	85 (43.6)	110 (56.7)
Creatinine clearance			
Mean± SD, ml/min	63.7 ± 1.5	63.3 ± 1.5	64.0 ± 1.5
Distribution			
>50ml/min	293 (75.3)	150 (76.9)	143 (73.7)
≤50ml/min	96 (24.7)	45 (23.1)	51 (26.3)
CHADS ₂ Score	2.0 ± 1.2	2.1 ± 1.2	2.0 ± 1.1
CHA ₂ DS ₂ -VASc Score	3.4 ± 1.4	3.5 ± 1.4	3.4 ± 1.4
HAS-BLED Score	1.1 ± 0.6	1.1 ± 0.6	1.1 ± 0.6

Atrial Fibrillation, no (%)	80 (20.6)	42 (21.5)	38 (19.6)
Antiplatelet drug, no (%)	67 (17.2)	33 (16.9)	34 (17.5)
New York Heart Association class			
Class III or IV, no (%)	26 (6.7)	13 (6.7)	13 (6.7)
Prosthetic valve position, no (%)			
Aortic only	339 (87.1)	168 (86.2)	171 (88.1)
Mitral only	37 (9.5)	20 (10.3)	17 (8.8)
Both	13 (3.3)	7 (3.6)	6 (3.1)
Initial dose of edoxaban			
Distribution, no (%)			
60mg		64 (32.8)	
30mg		131 (67.2)	

SD, standard deviation

430 Patients aged 18 to 85 years undergoing bioprosthetic valve replacement at the aortic and/or mitral position gave consent and were assessed for eligibility

20 were excluded
15 Did not meet eligibility criteria
5 Withdrew consent

410 Underwent randomization

205 Were assigned to receive edoxaban

205 Were assigned to receive warfarin

10 Withdrew before receipt of edoxaban

11 Withdrew before receipt of warfarin

195 Were included in the analysis


194 Were included in the analysis

20 Discontinued trial


17 Discontinued trial

175 Completed the trial

177 Completed the trial



A



No. at Risk

Edoxaban

195

188

181

178

Warfarin


194

182

181

177

B



No. at Risk

Edoxaban

195

188

181

178

Warfarin


194

183

181

177


C



No. at Risk

Edoxaban	195	187	179	176
Warfarin	194	183	181	177

D



No. at Risk	
Edoxaban	195
Warfarin	194
	187
	181
	179
	180
	176
	176

